We are live on ! Find out more
EBACW

European Biotech Acquisition Corp. Warrant
EBACW

Delisted

EBACW was delisted on the 2nd of March, 2023.

Back to rankings

29 hedge funds and large institutions have $858K invested in European Biotech Acquisition Corp. Warrant in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 32 → 29 (-3)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

69% less capital invested

Capital invested by funds: $2.73M → $858K (-$1.88M)

Holders
29
Holders Change
-3
Holders Change %
-9.38%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
2
Closed
6
Calls
$1.09M
Puts
–
Net Calls
+$1.09M
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$23.7K
2
Calamos Advisors
Calamos Advisors
Illinois
+$3.64K
3
PC
Periscope Capital
Ontario, Canada
+$546

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$1.84M
2
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$9K
3
ACA
Arena Capital Advisors
California
-$5.46K
4
FTCM
Fir Tree Capital Management
New York
-$5K
5
WP
Woodline Partners
California
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$661K – – –
AGC
2
Angelo Gordon & Co
New York
$132K – – –
PC
3
Periscope Capital
Ontario, Canada
$11K +$546 +5,000 +3%
MI
4
MMCAP International
Cayman Islands
$7K – – –
CS
5
Clear Street
New York
$7K +$23.7K +217,000 New
SC
6
Sculptor Capital
New York
$5K – – –
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$4K – – –
MCM
8
Moore Capital Management
New York
$4K – – –
CCM
9
CAAS Capital Management
New York
$3K – – –
LA
10
Linden Advisors
New York
$3K – – –
TCM
11
Tenor Capital Management
New York
$3K – – –
DCM
12
Dupont Capital Management
Delaware
$2K – – –
GCIA
13
Gabelli & Co Investment Advisers
New York
$2K – – –
GF
14
Gabelli Funds
New York
$2K – – –
WA
15
Whitebox Advisors
Minnesota
$2K – – –
Calamos Advisors
16
Calamos Advisors
Illinois
$2K +$3.64K +33,333 New
ACA
17
Arena Capital Advisors
California
$1K -$5.46K -50,000 -72%
AA
18
AQR Arbitrage
Connecticut
$1K – – –
ACM
19
Atalaya Capital Management
New York
$1K – – –
DCM
20
Difesa Capital Management
New York
$1K – – –
KL
21
KIM LLC
Kansas
$1K – – –
OAC
22
OMERS Administration Corp
Ontario, Canada
$1K – – –
State of Wisconsin Investment Board
23
State of Wisconsin Investment Board
Wisconsin
$1K – – –
VI
24
Vestcor Inc
New Brunswick, Canada
$1K – – –
MP
25
Mangrove Partners
Connecticut
– -$1.84M -187,740 Closed
1
2

EBACW Hedge Fund Activity: Q3 2022 in Review

29 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Warrant (EBACW) for Q3 2022, worth a combined $858K — down 69% from $2.73M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of EBACW and 3 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Clear Street, opening a new position worth an estimated $23.7K. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.84M sold.

  • 29 institutional investors held European Biotech Acquisition Corp. Warrant (EBACW) as of Q3 2022, down from 32 in Q2 2022.
  • Funds reported $858K of European Biotech Acquisition Corp. Warrant stock for Q3 2022, down 69% quarter-over-quarter.
  • 3 funds opened new European Biotech Acquisition Corp. Warrant positions in Q3 2022 and 6 closed out, a net change of -3 holders.
  • The largest European Biotech Acquisition Corp. Warrant buyer in Q3 2022 was Clear Street, an estimated $23.7K added.
  • The largest European Biotech Acquisition Corp. Warrant seller in Q3 2022 was Mangrove Partners, an estimated $1.84M sold.

Based on aggregated 13F filings for Q3 2022.